English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Patients with chronic liver disease are characterized by hepatic inflammation and the destruction of hepatocytes. Viral antigen-specific cytotoxic T lymphocytes, polyclonal cytokines, immune modulators, and oxidized biomolecules have been shown to induce damage and destruction of hepatocytes in these patients (Tsutsui et al., 2003). The contribution of oxidative stress per se to the chronic inflammatory state has been suggested, and consistent evidence has been afforded that both monocyte/macrophage activation and a defect in antioxidant systems occur early in the course of chronic liver failure and gradually increase with its progression to end-stage liver disease (Kirkham, 2007; Videla, 2009). Oxidative stress lead to formation of glycoxidation products, including advanced glycation endproducts (AGEs among them Ne(carboxymethyl)lysine (CML) is best known), and advanced oxidation protein products (AOPPs). AOPPs can be formed in vitro by exposure of serum albumin to hypochlorous acid. In vivo, plasma AOPPs are mainly carried by albumin and their concentrations are closely correlated with the levels of dityrosine. Within the heterogeneous group of AGEs, Ne-(carboxymethyl)lysine has been identified as a major AGEs in vivo (Reddy et al., 1995). Plasma concentrations of AGEs (closely correlating with AOPPs levels) increase with progression of chronic diseases (Witko-Sarsat et al., 1996; 1998), therefore CML has been considered as liver disease-related biomarker for oxidative stress (Sebekova et al., 2002; Yagmur et al., 2006).

intech ebooks

Circulating Advanced Oxidation Protein Products, Nε-(Carboxymethyl) Lysine and Pro-Inflammatory Cytokines in Patients with Liver Cirrhosis: Correlations with Clinical Parameters